Michael Feigh

2.3k total citations · 1 hit paper
58 papers, 1.4k citations indexed

About

Michael Feigh is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Michael Feigh has authored 58 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Epidemiology, 21 papers in Endocrinology, Diabetes and Metabolism and 20 papers in Molecular Biology. Recurrent topics in Michael Feigh's work include Liver Disease Diagnosis and Treatment (35 papers), Diet, Metabolism, and Disease (18 papers) and Metabolism, Diabetes, and Cancer (10 papers). Michael Feigh is often cited by papers focused on Liver Disease Diagnosis and Treatment (35 papers), Diet, Metabolism, and Disease (18 papers) and Metabolism, Diabetes, and Cancer (10 papers). Michael Feigh collaborates with scholars based in Denmark, United States and United Kingdom. Michael Feigh's co-authors include Sanne Skovgård Veidal, Niels Vrang, Henrik H. Hansen, Jacob Jelsing, Kristoffer T.G. Rigbolt, K.S. Tølbøl, Keld Fosgerau, Kristoffer Rigbolt, Jonathan D. Roth and Kim Henriksen and has published in prestigious journals such as Gastroenterology, PLoS ONE and Diabetes.

In The Last Decade

Michael Feigh

53 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

2020 200 citations Michael Feigh, Sanne Skovgård Veidal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Feigh Denmark	19	897	607	430	275	264	58	1.4k
C. Rychlicki Italy	15	771 0.9×	441 0.7×	519 1.2×	382 1.4×	293 1.1×	29	1.4k
Jamie E. Mells United States	10	987 1.1×	675 1.1×	447 1.0×	464 1.7×	205 0.8×	11	1.5k
Sara A. Beddow United States	9	779 0.9×	523 0.9×	768 1.8×	411 1.5×	87 0.3×	13	1.7k
Mark Naples Canada	26	457 0.5×	624 1.0×	576 1.3×	471 1.7×	40 0.2×	31	1.5k
Javier Vargas‐Castrillón Spain	10	980 1.1×	327 0.5×	397 0.9×	213 0.8×	150 0.6×	13	1.3k
Anja Kerksiek Germany	16	401 0.4×	255 0.4×	365 0.8×	434 1.6×	82 0.3×	27	1.0k
George G. Schweitzer United States	19	577 0.6×	377 0.6×	624 1.5×	278 1.0×	87 0.3×	33	1.4k
Virginia Pardo Spain	15	630 0.7×	159 0.3×	499 1.2×	156 0.6×	86 0.3×	28	1.3k
Francesca Saba Italy	18	466 0.5×	321 0.5×	243 0.6×	157 0.6×	165 0.6×	31	970
Véronique Fauveau France	14	447 0.5×	393 0.6×	544 1.3×	624 2.3×	63 0.2×	16	1.4k

Countries citing papers authored by Michael Feigh

Since Specialization

Citations

This map shows the geographic impact of Michael Feigh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Feigh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Feigh more than expected).

Fields of papers citing papers by Michael Feigh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Feigh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Feigh. The network helps show where Michael Feigh may publish in the future.

Co-authorship network of co-authors of Michael Feigh

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Feigh. A scholar is included among the top collaborators of Michael Feigh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Feigh. Michael Feigh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oró, Denise, Chen Zhang, Andreas Nygaard Madsen, et al.. (2024). Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. BMC Gastroenterology. 24(1). 59–59. 12 indexed citations

Sárvári, Anitta Kinga, Melvin Madsen, Lisbeth N. Fink, et al.. (2024). P154 Histological disease progression and ALK5i therapeutic efficacy in a chronic DSS-induced mouse model of IBD with intestinal fibrosis. Journal of Crohn s and Colitis. 18(Supplement_1). i454–i454. 1 indexed citations

Adorini, Luciano, Kristoffer Rigbolt, Michael Feigh, Jonathan D. Roth, & Mary Erickson. (2024). Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PLoS ONE. 19(4). e0300809–e0300809. 6 indexed citations

Ramachandran, Prakash, Madara Brice, Anna M. Hoy, et al.. (2024). Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767. Hepatology Communications. 8(12). 1 indexed citations

Oró, Denise, Susanne Elisabeth Pors, Ioannis Kamzolas, et al.. (2024). Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 328(1). G51–G71. 2 indexed citations

Shin, Gu‐Choul, Hyung Soon Park, Dongryeol Ryu, et al.. (2024). Paraoxonase‐2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non‐alcoholic steatohepatitis. British Journal of Pharmacology. 181(19). 3717–3742. 3 indexed citations

Sárvári, Anitta Kinga, et al.. (2023). HISTOPATHOLOGICAL CHARACTERIZATION OF A CHRONIC DSS-INDUCED MOUSE MODEL OF IBD WITH INTESTINAL FIBROSIS. Gastroenterology. 164(4). S6–S6.

Sárvári, Anitta Kinga, et al.. (2023). HISTOPATHOLOGICAL CHARACTERIZATION OF A CHRONIC DSS-INDUCED MOUSE MODEL OF IBD WITH INTESTINAL FIBROSIS. Inflammatory Bowel Diseases. 29(Supplement_1). S4–S4. 1 indexed citations

Hansen, Henrik H., Susanne Elisabeth Pors, Mogens Vyberg, et al.. (2023). Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Scientific Reports. 13(1). 23056–23056. 21 indexed citations

10.

Stokman, Geurt, Anita M. van den Hoek, Elsbet Pieterman, et al.. (2020). Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International. 40(11). 2860–2876. 15 indexed citations

11.

Veidal, Sanne Skovgård, Michael Feigh, Philip Hallenborg, et al.. (2020). Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Scientific Reports. 10(1). 1148–1148. 41 indexed citations

12.

Veidal, Sanne Skovgård, Christina Christoffersen, Michael Feigh, et al.. (2019). Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology. 19(1). 228–228. 12 indexed citations

13.

Roth, Jonathan D., Sanne Skovgård Veidal, Kristoffer Rigbolt, et al.. (2019). Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Scientific Reports. 9(1). 9046–9046. 44 indexed citations

14.

Tølbøl, K.S., Birgit Stierstorfer, Jörg F. Rippmann, et al.. (2018). Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences. 64(5). 1238–1256. 18 indexed citations

15.

Roth, Jonathan D., Michael Feigh, Sanne Skovgård Veidal, et al.. (2018). INT-767 improves histopathological features in a diet-inducedob/obmouse model of biopsy-confirmed non-alcoholic steatohepatitis. World Journal of Gastroenterology. 24(2). 195–210. 61 indexed citations

16.

Feigh, Michael, Sara Toftegaard Hjuler, Kim Vietz Andreassen, et al.. (2014). Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats. European Journal of Pharmacology. 737. 91–96. 15 indexed citations

17.

Feigh, Michael, Kim Vietz Andreassen, Sara Toftegaard Hjuler, et al.. (2013). Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats. Menopause The Journal of The North American Menopause Society. 20(7). 785–794. 19 indexed citations

18.

Feigh, Michael, A.V. Neutzsky-Wulff, Anne‐Christine Bay‐Jensen, et al.. (2012). Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta‐cell area and function in Zucker diabetic fatty rats. British Journal of Pharmacology. 167(1). 151–163. 23 indexed citations

19.

Neutzsky-Wulff, A.V., Kim Vietz Andreassen, Sara Toftegaard Hjuler, et al.. (2012). Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: How markers of β-cell loss may assist. Journal of Translational Medicine. 10(1). 214–214. 17 indexed citations

20.

Feigh, Michael, Kim Henriksen, Kim Vietz Andreassen, et al.. (2011). A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet‐induced obese rats. Diabetes Obesity and Metabolism. 13(10). 911–920. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact